Metabotropic glutamate receptor 5 in the pathology and treatment of schizophrenia

被引：71

作者：

Matosin, Natalie ^{[1
,2
]}

Newell, Kelly A. ^{[1
,2
]}

机构：

[1] Univ Wollongong, Sch Hlth Sci, Ctr Translat Neurosci, Illawarra Hlth & Med Res Inst, Wollongong, NSW 2522, Australia

[2] Schizophrenia Res Inst, Sydney, NSW 2010, Australia

来源：

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS | 2013年 / 37卷 / 03期

关键词：

mGluR5; mGlu5; Metabotropic glutamate receptor 5; Schizophrenia; NMDA receptor; Positive allosteric modulator; PAM; Antipsychotic; POSITIVE ALLOSTERIC MODULATOR; METHYL-D-ASPARTATE; LONG-TERM POTENTIATION; MESSENGER-RNA EXPRESSION; AMINO-ACID TRANSPORTER-2; RAT BEHAVIORAL-MODELS; IN-VIVO ACTIVITY; NMDA-RECEPTOR; PREFRONTAL CORTEX; PREPULSE INHIBITION;

D O I：

10.1016/j.neubiorev.2012.12.005

中图分类号：

B84 [心理学]; C [社会科学总论]; Q98 [人类学];

学科分类号：

03 ; 0303 ; 030303 ; 04 ; 0402 ;

摘要：

Metabotropic glutamate receptor 5 (mGluR5) potentiates the NMDA receptor (NMDAR) in brain regions implicated in schizophrenia, making it a viable therapeutic target for the treatment of this disorder. mGluR5 positive allosteric modulators may represent a valuable novel strategy for schizophrenia treatment, given the favourable profile of effects in preclinical paradigms. However it remains unclear whether mGluR5 also plays a causal or epiphenomenal role in NMDAR dysfunction in schizophrenia. Animal and cellular data suggest involvement of mGluR5, whilst post-mortem human studies remain inconclusive. This review will explore the molecular, animal and human data to support and refute the involvement of mGluR5 in the pathology of schizophrenia. Furthermore, this review will discuss the potential of mGluR5 modulators in the therapy of schizophrenia as well as aspects of mGluR5 that require further characterisation. (c) 2012 Elsevier Ltd. All rights reserved.

引用

页码：256 / 268

页数：13

共 50 条

[21] Metabotropic glutamate receptor 5 in bulimia nervosa
Mihov, Yoan
Treyer, Valerie
Akkus, Funda
Toman, Erika
Milos, Gabriella
Ametamey, Simon M.
Johayem, Anass
Hasler, Gregor
[J]. SCIENTIFIC REPORTS, 2020, 10 (01)
[22] Metabotropic glutamate receptor 5 in bulimia nervosa
Yoan Mihov
Valerie Treyer
Funda Akkus
Erika Toman
Gabriella Milos
Simon M. Ametamey
Anass Johayem
Gregor Hasler
[J]. Scientific Reports, 10
[23] PTSD and metabotropic glutamate receptor 5 regulation
不详
[J]. NEUROSCIENTIST, 2017, 23 (06): : 586 - 586
[24] Metabotropic Glutamate Receptor Subtype 5 and Encephalitis
Hof, Caitlin
Burris, Larry
[J]. NEUROLOGY, 2018, 90
[25] Metabotropic Glutamate Receptors As Emerging Targets for the Treatment of Schizophrenia
Dogra, Shalini
Conn, P. Jeffrey
[J]. MOLECULAR PHARMACOLOGY, 2022, 101 (05) : 275 - 285
[26] Discovery of BMS-955829, a potent positive allosteric modulator of metabotropic glutamate receptor 5 (mGluR5) for the treatment of schizophrenia
Degnan, Andrew P.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
[27] Metabotropic Glutamate Receptor and Endocannabinoid Signaling in the Prefrontal Cortex in Schizophrenia
Volk, David
Eggan, Stephen
Lewis, David
[J]. BIOLOGICAL PSYCHIATRY, 2010, 67 (09) : 13S - 13S
[28] Novel allosteric modulators of metabotropic glutamate receptors subtypes 2 and 5 for the treatment of schizophrenia
Jones, C. K.
Xiang, Z.
Jones, P. J.
Byun, N. E.
Hackler, E. A.
Rodriguez, A. L.
Ayala, J. E.
Niswender, C. M.
Jadhav, S.
Sheffler, D. J.
Hammond, A. S.
Barret, R.
Thompson, A. D.
Williams, R.
Gore, J. C.
Weaver, C. D.
Lindsley, C. W.
Conn, P. J.
[J]. NEUROPHARMACOLOGY, 2008, 55 (04) : 603 - 603
[29] OPPOSITE REGULATION OF METABOTROPIC GLUTAMATE RECEPTOR 3 AND METABOTROPIC GLUTAMATE RECEPTOR 5 BY INFLAMMATORY STIMULI IN CULTURED MICROGLIA AND ASTROCYTES
Berger, J. V.
Dumont, A. O.
Focant, M. C.
Vergouts, M.
Sternotte, A.
Calas, A. -G.
Goursaud, S.
Hermans, E.
[J]. NEUROSCIENCE, 2012, 205 : 29 - 38
[30] Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
Bita Moghaddam
[J]. Psychopharmacology, 2004, 174 : 39 - 44

← 1 2 3 4 5 →